Evidence map›Paper›PMID 28658112›Full record

Trial reportMedicine2017

Propofol decreases etomidate-related myoclonus in gastroscopy.

Jinfeng Liu, Rongfang Liu, Chao Meng, Zhenhua Cai, Xiaoqi Dai, Chao Deng, Jiahang Zhang, Huacheng Zhou

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Etomidate Sedation for Advanced Endoscopic Procedures.Digestive diseases and sciences · 2019
    Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jinfeng LiuDepartment of Anesthesiology, The Second Affiliated Hospital, Harbin Medical University, and the Hei Long Jiang Province Key Lab of Research on Anesthesiology and Critical Care Medicine, Harbin Affiliate Hospital of HeBei University Department of Anesthesiology, Affiliate Hospital of HeBei University, No.212 of Yuhua East Road, Baoding Department of Anesthesiology, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, China.
Rongfang Liu
Chao Meng
Zhenhua Cai
Xiaoqi Dai
Chao Deng
Jiahang Zhang
Huacheng Zhou
Harbin Medical University · CNSecond Affiliated Hospital of Harbin Medical University · CNAffiliated Hospital of Hebei University · CNFourth Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMyoclonus, a common complication during intravenous induction with etomidate, is bothersome to both anesthesiologists and patients. This study explored the preventive effect of pretreatment with propofol on etomidate-related myoclonus.

methodsThis was a prospective, double-blind, clinical, randomized controlled study. Totally, 363 patients who were scheduled for a short-duration, painless gastrointestinal endoscopy were divided into 5 groups. Four groups received 0 mg/kg (E group), 0.25 mg/kg (LPE group), 0.50 mg/kg (MPE group), or 0.75 mg/kg (HPE group) propofol pretreatment before etomidate anesthesia. Another group only received 1 to 2 mg/kg of propofol (P group) as anesthesia. The incidence and severity of myoclonus, patient circulation and respiratory status, and intraoperative and postoperative complications were recorded.

resultsThe incidence of myoclonus in the LPE group (26.8%), MPE group (16.4%), HPE group (14.9%), and P group (0) was lower than the E group (48.6%, P < .05). The incidence of grade 1, 2, and 3 of myoclonus in the LPE group, MPE group, HPE group, and P group was significantly lower than the E group, and that in the P group was lower than the LPE group (P < .05). The incidence of hypoxemia in the P group was higher than the E group, and the incidence of adverse events in the HPE group and P group was lower than the E group (P < .05). DISCUSSION: Pretreatment with propofol was feasible for preventing etomidate-related myoclonus. Furthermore, as propofol dosage increased, its effect on reducing the incidence and severity of myoclonic movements induced by etomidate increased.

Indexed as

GastroscopyAdolescentAdultAgedAged, 80 and overAnesthetics, IntravenousDose-Response Relationship, DrugDouble-Blind MethodEtomidateFemaleHemodynamicsHumansIncidenceMaleMiddle AgedMyoclonusAnesthetics, IntravenousEtomidatePropofol

Identifiers

PMID28658112
PMCPMC5500034
OpenAlexW2727908382

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.